10-Hydroxy-2,2-dimethyl-10-phenyl-2,10-dihydroimidazo[1,2-b]isoquinolin-5(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 10-Hydroxy-2,2-dimethyl-10-phenyl-2,10-dihydroimidazo[1,2-b]isoquinolin-5(3H)-one
• 英文别名: 10-hydroxy-2,2-dimethyl-10-phenyl-3H-imidazo[1,2-b]isoquinolin-5-one
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: SXRXRPFGHHOKQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻苯甲酰苯甲酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 70.0h， 生成 10-Hydroxy-2,2-dimethyl-10-phenyl-2,10-dihydroimidazo[1,2-b]isoquinolin-5(3H)-one
  参考文献：
  名称：

  Design and synthesis of tricyclic derivatives as high density lipoprotein cholesterol enhancers

  摘要：

  A pharmacophore for increasing HDLC was proposed based on common structural features of non-thio-containing compounds with HDLC enhancing properties. A search of the compound database identified various series of these non-thio-containing compounds, including a novel tricyclic imidazoisoquinolone. Preparation of 1-aryl-3-oxo-1,3- dihydro-2-benzofuran-1-carbooxamides using a novel and widely applicable one-step process from 2-acyl benzoic acids is reported. Reaction of diamines with 1-aryl-3-oxo-1,3-dihydro-2-benzofuran-1-carboxamides and related aza-analogues proceeded with regio-control to furnish imidazoisoquinolones, pyrimidoisoquinolones, and imidazonaphthqridines. NMR studies and X-ray crystallography confirmed the regiochemistry of the products. Compounds of these series increased concentrations of HDLC in test animals following oral administration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00668-5

文献信息

• Imidazo-isoquinolin-5-one derivatives, pyrimido-isoquinolin-6-one derivatives and imidazo-naphthyridin-5-one derivatives
  申请人：American Home Products Corporation

  公开号：US20020061900A1

  公开（公告）日：2002-05-23

  Antiatherosclerotic compounds are provided which have the following structure: 1 wherein: R is hydrogen, lower alkyl, alkenyl, alkynyl, aryl, heteroaryl, or aryl or heteroaryl substituted with one or more members of the group consisting of alkyl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, and halogen; D is C—H, carbon bound to R 5 or nitrogen; R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, alkyl, or taken together form a ring; R 5 is one or more groups selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, hydroxy, alkoxy, perfluoroalkyl, perfluoroalkoxy, alkylthio, nitro, amino, mono or di-alkylamino, or halogen; n is an integer of 0-3; or pharmaceutically acceptable salts thereof.

  提供具有以下结构的抗动脉粥样硬化化合物：其中：R为氢、较低的烷基、烯基、炔基、芳基、杂环芳基，或者芳基或杂环芳基，其上取代一个或多个由烷基、羟基、烷氧基、全氟烷基、全氟烷氧基、烷硫基、硝基、氨基、单烷基或二烷基氨基以及卤素组成的基团；D为C—H、与R5或氮相结合的碳；R1、R2、R3和R4各自独立地为氢、烷基，或者共同形成一个环；R5为氢、烷基、烯基、炔基、芳基、羟基、烷氧基、全氟烷基、全氟烷氧基、烷硫基、硝基、氨基、单烷基或二烷基氨基，或卤素中的一个或多个基团；n为0-3的整数；或其药用盐。
• US6448255B1
  申请人：——

  公开号：US6448255B1

  公开（公告）日：2002-09-10
• Design and synthesis of tricyclic derivatives as high density lipoprotein cholesterol enhancers
  作者：Hassan Elokdah、Sie-Yearl Chai、Douglas Ho、Theodore Sulkowski

  DOI：10.1016/s0960-894x(00)00668-5

  日期：2001.2

  A pharmacophore for increasing HDLC was proposed based on common structural features of non-thio-containing compounds with HDLC enhancing properties. A search of the compound database identified various series of these non-thio-containing compounds, including a novel tricyclic imidazoisoquinolone. Preparation of 1-aryl-3-oxo-1,3- dihydro-2-benzofuran-1-carbooxamides using a novel and widely applicable one-step process from 2-acyl benzoic acids is reported. Reaction of diamines with 1-aryl-3-oxo-1,3-dihydro-2-benzofuran-1-carboxamides and related aza-analogues proceeded with regio-control to furnish imidazoisoquinolones, pyrimidoisoquinolones, and imidazonaphthqridines. NMR studies and X-ray crystallography confirmed the regiochemistry of the products. Compounds of these series increased concentrations of HDLC in test animals following oral administration. (C) 2001 Elsevier Science Ltd. All rights reserved.